¿¬¼ö°­ÁÂ
Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷ : 2023-04-06

Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷ : 2023-04-06
±³À°ÀÏÀÚ : 2023-04-06
±³À°Àå¼Ò : ¾Ú¹ö¼­´õ ¼­¿ï Ç®¸¸È£ÅÚ

±³À°ÁÖÁ¦ : 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¿ìº´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 80,000¿ø  

ºñ°í Àü°øÀÇ,°£È£»ç,±âŸ 50000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:15~09:35 Current status of hemophilia care in China Renchi Yang(Institute of Haematology and Blood Diseases Hospital, China)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:35~09:55 Current Situation and Issues in Hemophilia in Japan Michio Sakai(Munakata Suikokai General Hospital, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:55~10:15 Current Situation and Issues in Hemophilia in Korea Ki-Young Yoo(Korea Hemophilia Foundation, Korea)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 10:15~10:35 Current Situation and Issues in Hemophilia in Taiwan Chia-Yao Chang(Taipei Medical University Hospital, Taiwan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 10:35~10:55 Current therapeutic landscape and future directions in the management of haemophilia in Australia Huyen Tran(Australia Haemophilia Centre Directors)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 11:20~12:00 Advances in hemophilia A treatment after emicizumab Midori Shima(Thrombosis and Hemostasis Research Center, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 12:10~12:50 Optimizing the benefits of personalized prophylaxis based on the real world experience Robert Klamroth(Vivantes Klinikum Friedrichshain, Germany)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:00~13:20 Emicizumab for Individual Needs of Japanese People Living with Hemophilia: Impacts and Unsolved Issues Ei Kinai(Tokyo Medical University, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:20~13:40 The role of low-dose prophylaxis and low-dose ITI for hemophilia children in developing countries. Runhui Wu(Beijing Children¡¯s Hospital, China)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:40~14:00 Individualized Treatment Using Population Pharmacokinetics for Patients with Hemophilia in Taiwan Yeu-Chin Chen(Tri-Service General Hospital, Taiwan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 14:00~14:20 Current treatment pattern in hemophilia, based upon data the HIRA(health insurance review agency) and KBDR (Korean bleeding disorder registry) Jung Woo Han(Yonsei University Health System, Korea)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 14:45~15:05 Hemophilia patients with Inhibitors in China Wei Liu(Blood Diseases Hospital (Institute of Hematology), China)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:05~15:25 The frontiers of diagnosis and treatment in Japanese hemophilia patients with inhibitors based on prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2) Koji Yada(National Hospital Organization Osaka National Hospital, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:25~15:45 Current status in hemophilia patients with inhibitors in Korea YoungShil Park(Kyung Hee University Hospital, Korea)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:45~16:05 Efficacy, safety, and cost of emicizumab prophylaxis in hemophilia A patients with inhibitor: a nationwide observation study in Taiwan Jiaan-Der Wang(Taichung Veterans General Hospital, Taiwan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 16:30~16:50 Clinical hemostasis prediction through current monitoring technology in bleeding disorders Naruto Shimonishi(Nara Medical University, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 16:50~17:10 The application of NGS for the diagnosis of hereditary platelet disorders Donglei Zhang(Zhongnan Hospital of Wuhan University, China)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 17:10~17:30 Laboratory monitor of factor VIII: perceive in the era of emicizumab Te-Fu Weng(Chung Shan Medical University Hospital, Taiwan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 17:30~17:50 Application of primary data of coagulometer assays Jae Woo Song(Yonsei University Health System, Korea)

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä) : 2024-02-25

±³À°ÀÏÀÚ : 2024-02-25 ±³À°Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø º»°ü ÁöÇÏ 1Ãþ ±èÁ¾±â Ȧ ±³À°ÁÖÁ¦ : ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä)ÁÖÃÖ±â°ü : ¼­

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,317 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇѳ»ºÐºñÇÐȸ SICEM 2024(1ÀÏÂ÷) : 2024-04-11

±³À°ÀÏÀÚ : 2024-04-11 ±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼­¿ï ±³À°ÁÖÁ¦ : SICEM 2024(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ ´ã´çÀÚ : ¹Ú¼öºó ¿¬¶ôó : 02-2038-0

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,097 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,182 , ´ñ±Û¼ö : 0

[±¤ÁÖ] ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd day : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ ÄÁº£¼Ç Ȧ ¿Ü 8°÷ ±³À°ÁÖÁ¦ : ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd dayÁÖÃÖ±â°ü : ´ëÇѽŰæ¿Ü°ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,937 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024³â Á¦75Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-04-17

±³À°ÀÏÀÚ : 2024-04-17 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ºÎ»ê ±³À°ÁÖÁ¦ : 2024³â Á¦75Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ ´ã´çÀÚ : °­ÈÆ ¿¬¶ôó

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,081 , ´ñ±Û¼ö : 0